PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-14.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-15.16%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.78%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.78%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
19.07%
Share count expansion well above AXSM's 0.11%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
19.07%
Diluted share count expanding well above AXSM's 0.11%. Michael Burry would fear significant dilution to existing owners' stakes.
-16.01%
Dividend reduction while AXSM stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-30.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
87.33%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
68.32%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-1414.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
92.17%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
80.18%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1411.37%
Positive growth while AXSM is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-77.60%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-28.05%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
13.37%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
-15.85%
We’re deleveraging while AXSM stands at 4.37%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
22.47%
R&D growth drastically higher vs. AXSM's 17.50%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.59%
We cut SG&A while AXSM invests at 63.62%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.